Mini Review

Open Access

Is there a truly traceable track for the tumor target?

Abstract

The author recorded the history of both the attempts at cancer cure and how the autopsy had been revealing nature`s principles regarding possible target therapy. Actually, the visionary views of the medical masters of yester years pointed to present prospects of target therapy. Indeed, the author is persuaded that there is a traceable track which the translational system should seek because it is likely to be effective in looking for the target therapy of cancer.

Keywords: cancer, history, choriocarcinoma, cure, general principles

Volume 2 Issue 3 - 2018

Wilson IB Onuigbo
Pathology Department, Medical Foundation and Clinic, Nigeria

Correspondence: Wilson IB Onuigbo, Pathology Department, Medical Foundation & Clinic, 8 Nsukka Lane, Enugu 400001, Nigeria, Tel +2348037208680, Email wilson.onuigbo@gmail.com

Received: February 26, 2018 | **Published:** June 04, 2018

Mini review

Cancer treatment has long bothered mankind. The modern trend was well appreciated by Sir Michael Woodruff.[1] As he put it in a Review Lecture back in 1973, cancer is man's "elusive enemy."

The author documented the age-old problems of dispensing curative drugs.[2] This was done in conjunction with human models in cancer metastasis research.

A personal paper also presented the visionary views of the medical masters of yester years.[3] In particular, these were directed to understanding Nature's norms which point to present prospects concerning the target therapy of cancer. From another angle, it was shown that the old autopsy experience was revealing Nature's principles for advancing current cancer research including target therapy.[4] Moreover, it was asked whether there was a translational system suitable for the target therapy of lung cancer in particular.[5]

The answer can be based on the Mono-Block Formalin-Fixation Method for investigating lung cancer.[6] Using it, the thoracic duct was obtained as one whole, then Swiss-rolled and finally cut as a single microscope slide.[7] Thereafter, it was seen that, when erythrocytes are commingled with cancer cells, **necrosis** occurs in this lymphatic microenvironment.[8]

It has since been argued that such necrosis is due to an underlying Natural Factor which should be called the "Erythrocyte Necrosis Associated Factor".[9] In all probability, purposive researches should reveal this Factor when carried out in order strictly thus:

a. Cannulating of the thoracic duct.[10]

b. Using consenting patients.[11]

c. Employing the intravital videomicroscope.[12]

Indeed, the author's experience was the serendipitous one not only seeing *lively* cancer cells but also *necrotic* cancer cells with aggregated red cells.[7] In other words, the requirements of 2 subsets in research were occurring in this microenvironment.[13] In order to further strengthen the enticing theory, one should propose some angles for its validation.[14–16]

Now, there was a time that choriocarcinoma was in a similar situation.[17] Then, Roy Hertz discovered its cure.[18] Therefore, there is now the need for other conquests with special reference to the target therapy of cancer.

In this connection, Thiele and Sleeman instanced "Recent advances in understanding the biopsy of lymphangiogenesis, the new growth of lymphatic vessels".[19] Incidentally, as far back as 1963, the author delineated the position of the earliest deposits of lung cancer deposits in centrifugally disposed abdominal lymph nodes.[20] Indeed, with 6 comments, such newness of growth was mentioned. Perhaps, the lack of the key-word system at that time prevented the recognition of this phenomenon earlier.[21,22]

It is great that Gurt recently outlined cancer drug development in new targets for cancer treatment.[23] Moreover, Chabner and Roberts have also chronicled the history of modern chemotherapy and identified the remaining challenges for the next generation of researches.[24] Indeed, there is need to support their own challenge and that of Coleman[25] who pointed to the influencing role of the medical-industrial complex.

Conclusion

This mini-review has been based with personal choice on lung cancer because it is a superlatively located growth whose dispersed deposits surprisingly manifest as many as 10 anomalies.[26] In this context, Melville Arnott,[27] during an exciting Memorial Lecture in 1955, advised that anomalies should always be worthy of research because they are Nature's ways of indicating such fronts. Indeed, in this mini-review, the pointing has been to the truly traceable track on which the efforts of translational researches should end with the target therapy of man's "elusive enemy!"

Acknowledgments

None.

Conflict of interest

Author declares no conflict of interest.

References

1. Woodruff M. Review Lecture: Cancer–an elusive enemy. *Proc R Soc London*. 1973;183:87–104.
2. Onuigbo WIB. *Human model for curing cancer after age-old problems*

for dispensing of drugs. In: Human models in cancer metastasis research. Lap Lambert Academic Publishing GmbH & Co. KG, Saarbrucken, Germany; 2011:63–69.

3. Onuigbo WIB. The visionary views of medical masters of yester years on Nature's norms point to present prospects in the target therapy of cancer. *Biol Med*. 2015;7:221.
4. Onuigbo WIB. The autopsy reveals nature's principles for advancing current cancer research including target therapy: A review. *Trans Med*. 2016;6(4):1–7.
5. Onuigbo WIB. Is there a natural translational system suitable for the target therapy of lung cancer? *Trans Med*. 2014;4:2.
6. Onuigbo WIB. A mono-block formalin-fixation method for investigating cancer metastasis. *Z Krebsforsch*. 1963;65:209–210.
7. Onuigbo WIB. The carriage of cancer cells by the thoracic duct. *Br J Cancer*. 1967;21(3):496–500.
8. Onuigbo WIB. Nature's necrosis factor when associated with erythrocytes may not only explain the surprises in lung cancer metastasis but also suggest target therapy. *Med Hypotheses*. 2013;80(6):698–700.
9. Mittleider D, Dykes TA, Cicuto KP, et al. Retrograde cannulation of the thoracic duct and embolization of the cisterna chyli in treatment of chylous ascites. *J Vasc Intervent Radiol*. 2008;19(2 Pt 1):285–290.
10. Onuigbo WIB. Historical origins of informed consent in cancer surgery. *J Forensic Res*. 2014;5:246–247.
11. Chambers AF, MacDonalt IC, Schmidt EE, et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. *Cancer Metastasis Rev*. 1995;14(4):279–302.
12. Onuigbo WIB. Hypothesis: Nature has provided the two subsets required for translational lung cancer research. *Intl J Cell Sci Mol Biol*. 2016;1(1).
13. Onuigbo WIB. The occurrence of a high number of lung cancer metastases is consonant with the proposed theory of "Erythrocyte Associated Necrosis Factor, *Trans Med*. 2016;7:2.
14. Onuigbo WIB. Nature's intrinsic "Erythrocyte Associated Necrosis Factor" (EANF) can explain cancer regression. *Res Chron Hlth Sci*. 2016;2(2):266–268.
15. Onuigbo WIB. Does the Erythrocyte Associated Necrosis Factor explain the scarcity of metastases in the spleen? *Trans Med*. 2016;6(3):177.
16. Onuigbo WIB. Nature's intrinsic Erythrocyte Associated Necrosis Factor. (EANF) explains the anomalous lack of metastases in "bulky" lung cancers. *Arch Cancer Res*. 2016.
17. Hertz R, Bergenstal DM, Lipsett MB, et al. Chemotherapy of choriocarcinoma and related trophoblastic tumors in women. *JAMA*. 1958;168(7):845–854.
18. Yarris JP, Hunter AJ. Roy Hertz, M.D. (1909-2002): the cure of choriocarcinoma and its impact on the development of chemotherapy for cancer. *Gynecol Oncol*. 2003;89(2):193–198.
19. Thiele W, Sleeman JP. Tumor-induced lymphangiogenesis: A target for cancer therapy? *J Biotechnol*. 2006;124(1):224–241.
20. Onuigbo WIB. A modified theory of retrograde lymphatic metastasis in lung cancer. *Br J Dis Chest*. 1963;57:120–125.
21. Onuigbo WIB. *Clarification of premature discovery in science in terms of higher education and broader communication.* Eric Education Resources Information Center, 2009.
22. Wilson IB Onuigbo. Lymphangiogenesis in cancer: A Review. *Biochemistry & Physiology*. 2014;3:3.
23. Curt GA. Cancer drug development: New targets for cancer treatment. *Oncologist*. 1996;1(3):2–3.
24. Chabner BA, Roberts TG. Chemotherapy and the war on cancer. *Nature Reviews Cancer*. 2005;5:65–72.
25. Coleman MP. War on cancer and influence of the medical-Industrial complex. *J Cancer Policy*. 2013;1(3–4):31–34.
26. Onuigbo WIB. Ten anomalous patterns of lung cancer spread with single explanatory hypothesis. *Med Hypoth*. 2000;55(3):227–231.
27. Arnott M. The climate of discovery. *Lancet*. 1955;269(6894):783–785.